

## **Shape and size mimicry in the design of ternary molecular solids: Towards a robust strategy for crystal engineering**

Srinu Tothadi, Arijit Mukherjee and Gautam R. Desiraju

Solid State and Structural Chemistry Unit, Indian Institute of Science, Bangalore, India

Fax: +91 80 23602306; Tel: +91 80 22933311; E-mail: desiraju@sscu.iisc.ernet.in

### Supplementary Information

Contents	Page no
1. Experimental details	2
2. Crystallographic information.	5
3. ORTEP diagrams.	8

## Experimental Section

### Single crystal X-ray diffraction

Single crystal X-ray data for all crystals were collected on a Rigaku Mercury375/M CCD (XtaLAB mini) diffractometer using graphite monochromated Mo-K $\alpha$  radiation at 150 K and the data were processed with Rigaku Crystal clear software<sup>1</sup>. Structure solution and refinement were performed using SHELX-97<sup>2</sup> using the WinGX suite<sup>3</sup>. Refinement of coordinates and anisotropic thermal parameters of non-hydrogen atoms were carried out by the full-matrix least-squares method. Mercury version 2.3 was used for molecular representations and packing diagrams.

1. CrystalClear 2.0, Rigaku Corporation, Tokyo, Japan.
2. G. M. Sheldrick, SHELXTL V5.1; Madison, WI, 1998.
3. L. J. Farrugia, *J. Appl. Crystallogr.* 1999, **32**, 837–838.

### Crystallization

*Orcinol* : 4,4'-bipyridine (**1**). Both the compounds were taken in 1:1 ratio and ground together in a mortar and with a pestle for ten minutes. Then the powder obtained was dissolved in MeOH. Crystals were obtained by slow evaporation of solvent after 2-3 days. The same co-crystal was obtained when orcinol and 4,4'-bipyridine were taken in 1: 2 ratios and ground in a mortar. In that case crystal was obtained from 1,4-dioxane by slow evaporation.

*Orcinol* : 4,4'-bipyridine (**2**). An equimolar mixture of orcinol and 4,4'-bipyridine was ground with 2-3 drops of EtOH (solvent drop grinding). The ground sample was dissolved in a minimum amount of MeCN and crystals of the 2:3 cocrystal, suitable for X-ray diffraction, were obtained after four days.

*2-Methylresorcinol : 4,4'-bipyridine (3)*. An equimolar mixture of 2-methylresorcinol and 4,4'-bipyridine were ground with 2-3 drops of EtOH. The ground sample was dissolved in the minimum amount of 1:1 DMSO–CHCl<sub>3</sub> and crystals of the 2:3 compound, suitable for X-ray diffraction, were obtained after five days.

*Orcinol : 4,4'-bipyridine: phenazine (4)*. Orcinol, 4,4'-bipyridine and phenazine were taken in 2:2:1 ratio and ground in a mortar after addition of few drops of MeOH by solvent drop grinding method. The powder obtained was then dissolved in a series of solvents. Yellow colored crystals were obtained from MeOH after three days.

*Orcinol : 4,4'-bipyridine : acridine (5)*. Orcinol, 4,4'-bipyridine and acridine were taken in 2:2:1 ratio and ground in a mortar after addition of few drops of MeOH. The powder obtained was then dissolved in a series of solvents. Pale yellow colored crystals were obtained from MeCN and MeOH after 3 days.

*Orcinol : 4,4'-bipyridine : anthracene (6)*. Orcinol, 4,4'-bipyridine and acridine were taken in 2:2:1 ratio and ground in a mortar after addition of few drops of MeOH. The powder obtained was then dissolved in a series of solvents. Crystals were obtained from THF after 3 days by slow evaporation of solvent.

*Orcinol : 4,4'-bipyridine : 2,2'-bithiophene (7)*. A 2:2:1 molar mixture of orcinol, 4,4'-bipyridine and 2,2'-bithiophene were ground with 2-3 drops of EtOH. Then the ground sample was dissolved in a minimum amount of <sup>i</sup>PrOH and crystals of the 2:2:1 compound, suitable for X-ray diffraction, were obtained after four days.

*2-Methylresorcinol : 4,4'-bipyridine : biphenyl (8)*. 2:2:1 Molar equivalents of 2-methylresorcinol, 4,4'-bipyridine and biphenyl were ground with 2-3 drops of EtOH. Then the ground sample was dissolved in a minimum amount of 1,4-dioxane and crystals of the 2:2:1 compound, suitable for X-ray diffraction, were obtained after seven days.

*2-Methylresorcinol : 4,4'-bipyridine : biphenyl (9)*. 2:1:1 Molar equivalents of 2-methylresorcinol, 4,4'-bipyridine and biphenyl were ground with 2-3 drops of EtOH. The ground sample was dissolved in a minimum amount of 1,4-dioxane and crystals of the 2:1:1, compound, suitable for X-ray diffraction, were obtained after six days.

*2-Methylresorcinol : 4,4'-bipyridine : 2,2'-bithiophene (10)*. A 2:2:1 mixture of 2-methylresorcinol, 4,4'-bipyridine and 2,2'-bithiophene was ground with 2-3 drops of EtOH. Then the ground sample was dissolved in a minimum amount of *i*PrOH and crystals of the 2:2:1 ternary compound, suitable for X-ray diffraction, were obtained after 4 days.

*2-Methylresorcinol : 4,4'-bipyridine : 2,2'-bithiophene (11)*. 2:1:1 Molar equivalents of 2-methylresorcinol, 4,4'-bipyridine and 2,2'-bithiophene were ground with a few drops of EtOH. The ground sample was dissolved in a minimum amount of MeCN and crystals of the 2:1:1 compound, suitable for X-ray diffraction, were obtained after 3 days.

*2-Methylresorcinol : 4,4'-bipyridine : pyrene (12)*. A 2:2:1 mixture of 2-methylresorcinol, 4,4'-bipyridine and pyrene was ground with 2-3 drops of EtOH. The ground sample was dissolved in a minimum amount of MeOH and crystals of the 4:3:2 compound, suitable for X-ray diffraction, were obtained after 6 days.










*2-Methylresorcinol : 4,4'-bipyridine : phenazine (13)*. 2-Methylresorcinol, 4,4'-bipyridine and phenazine were taken in 2:2:1 ratio and ground in a mortar after addition of a few drops of MeOH. The powder obtained was then dissolved in a series of solvents. Crystals were obtained from THF after 2 days by slow evaporation of the solvent.





## 2. Crystallographic information

	1	2	3	4	5	6
	Orcinol : 4,4'-bipyridine	Orcinol : 4,4'-bipyridine	2-Methylresorcinol : 4,4'-bipyridine	Orcinol : 4,4'-bipyridine : phenazine	Orcinol : 4,4'-bipyridine : acridine	Orcinol : 4,4'-bipyridine : anthracene
<i>Formula</i>	(C <sub>10</sub> H <sub>8</sub> N <sub>2</sub> ) <sub>3</sub> ·(C <sub>7</sub> H <sub>8</sub> O <sub>2</sub> ) <sub>2</sub>	(C <sub>10</sub> H <sub>8</sub> N <sub>2</sub> ) <sub>3</sub> ·(C <sub>7</sub> H <sub>8</sub> O <sub>2</sub> ) <sub>2</sub>	(C <sub>10</sub> H <sub>8</sub> N <sub>2</sub> ) <sub>3</sub> ·(C <sub>7</sub> H <sub>8</sub> O <sub>2</sub> ) <sub>2</sub>	(C <sub>12</sub> H <sub>8</sub> N <sub>2</sub> )·(C <sub>10</sub> H <sub>8</sub> N <sub>2</sub> ) <sub>2</sub> ·(C <sub>7</sub> H <sub>8</sub> O <sub>2</sub> ) <sub>2</sub>	(C <sub>13</sub> H <sub>9</sub> N)·(C <sub>10</sub> H <sub>8</sub> N <sub>2</sub> ) <sub>2</sub> ·(C <sub>7</sub> H <sub>8</sub> O <sub>2</sub> ) <sub>2</sub>	(C <sub>14</sub> H <sub>10</sub> )·(C <sub>10</sub> H <sub>8</sub> N <sub>2</sub> ) <sub>2</sub> ·(C <sub>7</sub> H <sub>8</sub> O <sub>2</sub> ) <sub>2</sub>
<i>Formula weight</i>	716.82	716.82	716.82	740.84	739.85	738.86
<i>Crystal System</i>	Triclinic	Orthorhombic	Triclinic	Triclinic	Triclinic	Triclinic
<i>Space group</i>	<i>P</i> $\bar{1}$	<i>Pbca</i>	<i>P</i> $\bar{1}$	<i>P</i> $\bar{1}$	<i>P</i> $\bar{1}$	<i>P</i> $\bar{1}$
<i>a</i> (Å)	8.8290(18)	9.346(6)	7.4790(15)	9.4283(10)	9.3265(7)	9.2102(9)
<i>b</i> (Å)	10.079(2)	23.250(15)	14.911(3)	10.1821(10)	10.3739(8)	10.4824(11)
<i>c</i> (Å)	12.092(2)	33.59(2)	18.243(4)	11.1549(11)	11.1923(8)	11.2645(11)
<i>α</i> (°)	67.68(3)	90	110.11(3)	69.876(5)	68.503(5)	68.340(5)
<i>β</i> (°)	77.45(3)	90	90.79(3)	86.613(6)	86.581(6)	88.208(6)
<i>γ</i> (°)	69.16(3)	90	102.61(3)	69.427(5)	69.849(5)	70.827(5)
<i>V</i> (Å <sup>3</sup> )	926.1(4)	7299(8)	1855.6(7)	939.04(17)	943.12(13)	949.65(17)
<i>Z</i>	1	8	2	1	1	1
<i>ρ<sub>calc</sub></i> (gcm <sup>-3</sup> )	1.285	1.305	1.283	1.310	1.304	1.292
<i>F</i> (000)	378	3024	756	390	390	390
<i>μ</i> (mm)	0.084	0.085	0.084	0.085	0.085	0.083
<i>Temp</i> (K)	150	150(2)	150 (2)	150	150	150
<i>Total ref.</i>	9829	55276	19860	9968	10093	10154
<i>Unique ref.</i>	4209	8337	8511	4305	4319	4345
<i>Observed ref. (I &gt; 2σ(I))</i>	2926	6722	5557	3306	3679	3653
<i>R</i>	0.0653	0.0996	0.0736	0.0510	0.0509	0.0427
<i>wR2</i>	0.2191	0.2708	0.2365	0.1291	0.1471	0.1188
<i>S</i>	1.10	1.186	1.046	1.04	1.08	1.07
<i>CCDC No.</i>	836446	836451	836442	836450	836448	836449

	7	8	9	10	11	12	13
	Orcinol : 4,4'-bipyridine : 2,2'-bithiophene	2-Methylresorcinol : 4,4'-bipyridine : biphenyl	2-Methylresorcinol : 4,4'-bipyridine : biphenyl	2-Methylresorcinol : 4,4'-bipyridine : 2,2'-bithiophene	2-Methylresorcinol : 4,4'-bipyridine : 2,2'-bithiophene	2-Methylresorcinol : 4,4'-bipyridine : pyrene	2-Methylresorcinol : 4,4'-bipyridine : phenazine
<b>Formula</b>	(C <sub>10</sub> H <sub>8</sub> N <sub>2</sub> )·(C <sub>7</sub> H <sub>8</sub> O <sub>2</sub> )·(C <sub>8</sub> H <sub>6</sub> S <sub>2</sub> ) <sub>0.5</sub>	(C <sub>12</sub> H <sub>10</sub> )·(C <sub>10</sub> H <sub>8</sub> N <sub>2</sub> ) <sub>2</sub> ·(C <sub>7</sub> H <sub>8</sub> O <sub>2</sub> ) <sub>2</sub>	(C <sub>12</sub> H <sub>10</sub> )·(C <sub>10</sub> H <sub>8</sub> N <sub>2</sub> )·(C <sub>7</sub> H <sub>8</sub> O <sub>2</sub> ) <sub>2</sub>	(C <sub>10</sub> H <sub>8</sub> N <sub>2</sub> )·(C <sub>7</sub> H <sub>8</sub> O <sub>2</sub> )·(C <sub>8</sub> H <sub>4</sub> S <sub>2</sub> ) <sub>0.5</sub>	(C <sub>10</sub> H <sub>8</sub> N <sub>2</sub> )·(C <sub>7</sub> H <sub>8</sub> O <sub>2</sub> ) <sub>2</sub> ·(C <sub>8</sub> H <sub>4</sub> S <sub>2</sub> )	(C <sub>16</sub> H <sub>10</sub> ) <sub>2</sub> ·(C <sub>10</sub> H <sub>8</sub> N <sub>2</sub> ) <sub>3</sub> ·(C <sub>7</sub> H <sub>8</sub> O <sub>2</sub> ) <sub>4</sub>	(C <sub>12</sub> H <sub>8</sub> N <sub>2</sub> )·(C <sub>10</sub> H <sub>8</sub> N <sub>2</sub> )·(C <sub>7</sub> H <sub>8</sub> O <sub>2</sub> ) <sub>2</sub>
<b>Formula weight</b>	363.45	714.84	558.65	362.44	570.72	1241.40	584.66
<b>Crystal System</b>	Monoclinic	Monoclinic	Monoclinic	Triclinic	Monoclinic	Triclinic	Monoclinic
<b>Space group</b>	<i>P</i> 2 <sub>1</sub> / <i>c</i>	<i>C</i> 2/ <i>c</i>	<i>P</i> 2 <sub>1</sub>	<i>P</i> $\bar{1}$	<i>P</i> 2 <sub>1</sub> / <i>c</i>	<i>P</i> $\bar{1}$	<i>P</i> 2 <sub>1</sub> / <i>c</i>
<b><i>a</i> (Å)</b>	9.3357(12)	26.380(5)	7.737(4)	7.4470(15)	7.827(6)	7.509(6)	7.6576(9)
<b><i>b</i> (Å)</b>	12.3050(14)	7.5320(15)	19.791(10)	9.4240(19)	18.987(14)	8.755(6)	19.710(2)
<b><i>c</i> (Å)</b>	17.910(2)	19.030(4)	9.508(5)	14.075(3)	11.956(6)	24.70(2)	11.6365(12)
<b><i>α</i> (°)</b>	90	90	90	72.08(3)	90	91.768(12)	90
<b><i>β</i> (°)</b>	116.558(7)	101.93(3)	95.170(7)	76.66(3)	126.99(3)	96.793(14)	125.572(7)
<b><i>γ</i> (°)</b>	90	90	90	89.64(3)	90	93.035(13)	90
<b><i>V</i> (Å<sup>3</sup>)</b>	1840.3(4)	3699.5(13)	1450.0(13)	912.3(4)	1419.2(18)	1609(2)	1428.6(3)
<b><i>Z</i></b>	4	4	2	2	2	1	2
<b><i>ρ</i><sub>calc</sub> (gcm<sup>-3</sup>)</b>	1.312	1.283	1.280	1.319	1.336	1.281	1.359
<b><i>F</i>(000)</b>	764	1512	592	380	600	652	616
<b><i>μ</i>(mm)</b>	0.193	0.083	0.083	0.195	0.228	0.081	0.090
<b>Temp(K)</b>	150(2)	150 (2)	150 (2)	150 (2)	150 (2)	150 (2)	150
<b>Total ref.</b>	19129	18432	15099	9717	14493	17140	14793
<b>Unique ref.</b>	4212	4281	6630	4166	3250	7370	3280
<b>Observed ref. (<i>I</i> &gt; 2σ(<i>I</i>))</b>	3744	2962	6082	3373	2807	4555	2732
<b><i>R</i></b>	0.0579	0.0878	0.0570	0.0605	0.0543	0.0677	0.0420
<b><i>wR</i>2</b>	0.1682	0.2559	0.1620	0.2001	0.1730	0.2283	0.1023
<b><i>S</i></b>	1.067	1.169	1.054	1.107	1.053	1.079	1.05
<b>CCDC No.</b>	836452	836443	836592	836441	836445	836444	836447

**3. ORTEP Diagrams (only the asymmetric unit is shown)**

		
<p>Orcinol : 4,4'-bipyridine <b>(1)</b></p>	<p>Orcinol : 4,4'-bipyridine <b>(2)</b></p>	<p>2-Methylresorcinol : 4,4'-bipyridine <b>(3)</b></p>
		
<p>Orcinol : 4,4'-bipyridine : phenazine <b>(4)</b></p>	<p>Orcinol : 4,4'-bipyridine : acridine <b>(5)</b></p>	<p>Orcinol : 4,4'-bipyridine : anthracene <b>(6)</b></p>
		
<p>Orcinol : 4,4'-bipyridine : 2,2'-bithiophene <b>(7)</b></p>	<p>2-Methylresorcinol : 4,4'-bipyridine : biphenyl <b>(8)</b></p>	<p>2-Methylresorcinol : 4,4'-bipyridine : biphenyl <b>(9)</b></p>

		
<p>2-Methylresorcinol : 4,4'- bipyridine : 2,2'-bithiophene <b>(10)</b></p>	<p>2-Methylresorcinol : 4,4'- bipyridine : 2,2'-bithiophene <b>(11)</b></p>	<p>2-Methylresorcinol : 4,4'- bipyridine : pyrene <b>(12)</b></p>
		
<p>2-Methylresorcinol : 4,4'- bipyridine : phenazine <b>(13)</b></p>		